Jemperli
Jemperli ingredients
| Active ingredient | Strength |
|---|---|
| Dostarlimab | 50 mg/mL |
What Jemperli is used for
The FDA lists the approved uses on the official label (below). In the EU, dostarlimab is approved as Jemperli for:
Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Jemperli
- Generic name
- Dostarlimab
- Made by
- GlaxoSmithKline LLC
- Forms
- Injection
- Given
- Intravenous
- Drug class
- Programmed Death Receptor-1 Blocking Antibody
- FDA approval
- Biologic licence (BLA) BLA761174
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Dostarlimab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Jemperli?
Jemperli (Dostarlimab) is a cancer medicine made by GlaxoSmithKline LLC, approved by the US FDA.
What are the ingredients of Jemperli?
Jemperli contains Dostarlimab (50 mg/mL).
Is Jemperli approved in Europe?
The same active substance is approved in the EU as Jemperli.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA